Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(13 sites) United States
City of Hope Medical Center, Duarte, California Stanford Cancer Institute, Palo Alto, California University of Miami Health System, Miami, Florida The University of Kansas Cancer Center, Westwood, Kansas Johns Hopkins Hospital, Baltimore, Maryland Dana Farber Cancer Institute, Boston, Massachusetts Washington University School of Medicine, St Louis, Missouri Icahn School of Medicine At Mount Sinai, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York Wake Forest Baptist Medical Center, Winston-Salem, North Carolina Cleveland Clinic, Cleveland, Ohio Vanderbilt University Medical Center, Nashville, Tennessee Md Anderson Cancer Center, Houston, Texas